JW (Cayman) Therapeutics Co Ltd

Common Name
JW (Cayman) Therapeutics
Country
China (Mainland)
Sector
Healthcare
Industry
Biotechnology
Employees
292
Ticker
2126
Exchange
HONG KONG EXCHANGES AND CLEARING LTD
Description
JW (Cayman) Therapeutics Co. Ltd. is a biopharmaceutical company focused on developing, manufacturing, and commercializing cell-based immunotherapies. The company primarily engages in the field of onc...

JW (Cayman) Therapeutics's Climate Target Data Preview

As of 2023, JW (Cayman) Therapeutics has disclosed 1 climate targets aimed at reducing its greenhouse gas (GHG) emissions. These include 1 intensity-based target, signaling the company’s commitment to managing and lowering its carbon footprint over time. The targets span various emissions scopes and time horizons, offering insight into JW (Cayman) Therapeutics ’s climate strategy, ambition level, and alignment with global decarbonization goals.

Target TypeScope of TargetUnitTargetTarget Year
Intensity-based Target
Scope 1 - Total, Scope 2 - Total
Metric Tonnes of CO2 equivalent (mtCO2e) per Renminbi/Chinese Yuan (RMB) of Revenue
Copy restricted. Please purchase to unlock this data.
a
2025
Download JW (Cayman) Therapeutics's Climate Targets data for free

Create your Tracenable account today and download up to 5 company datasets of your choice for free. No credit card required.

Verified Sources Behind JW (Cayman) Therapeutics’s Climate Targets Data

Every figure on this dashboard has a transparent audit trail. With Tracenable, each data point is traceable back to its original source, viewable directly inside our platform. Explore JW (Cayman) Therapeutics’s data sources below and access millions more through our Disclosure Search.

a. JW (Cayman) Therapeutics's ESG Report 2023
Trace every data point back to JW (Cayman) Therapeutics’s disclosures

Sign up for Tracenable and access millions of corporate disclosures, including annual reports and sustainability filings from global companies, completely free of charge.

Insights into JW (Cayman) Therapeutics's Greenhouse Gas Emissions Pathways

As of 2023, JW (Cayman) Therapeutics has set greenhouse gas (GHG) emissions reduction targets that cover its operational emissions (Scope 1 and 2), but not its value chain emissions (Scope 3). This means its reduction efforts currently focus on direct and purchased energy emissions. a

Does JW (Cayman) Therapeutics have a target to reduce the emissions from its operations?

As of 2023, JW (Cayman) Therapeutics has set a target to reduce its operational greenhouse gas (GHG) emissions, specifically those from Scope 1 and Scope 2 sources. a

JW (Cayman) Therapeutics's most ambitious operational target is to reduce these emissions by 40% by 2025, compared to a baseline of 0 Metric Tonnes of CO2 equivalent (mtCO2e) per Renminbi/Chinese Yuan (RMB) of Revenue in 2021. a

JW (Cayman) Therapeutics has already surpassed its operational emissions reduction target, with 2023 levels falling below the 2025 value, achieving its climate goal ahead of schedule. a

JW (Cayman) Therapeutics's Operational (Scope 1+2) Emissions Pathway

20212023202500000BaselineCurrent (-84%)Target 2025 (-40%)
Want Full Access to JW (Cayman) Therapeutics's Climate Targets Dataset?
Sign Up